KOSDAQ-listed company Neofect announced on the 25th that it has secured exclusive licenses for two core bio-material technologies derived from salmon. One technology is a key method for mass-producing PDRN (polydeoxyribonucleotide) and PN (polynucleotide), specifically "a method for extracting genes (DNA) with varying content from salmonid fish germ cells for different applications." The other is "a method for producing high-purity proteoglycan derived from salmon cartilage and its applications."
An exclusive license grants the holder the sole right to use the relevant patent. With these licenses, Neofect has established a foundation for the mass extraction and commercialization of PDRN, PN, and proteoglycan ingredients.
PDRN and PN are substances obtained from salmon DNA, known for their outstanding cell regeneration and anti-aging effects. They are already recognized as key ingredients in the global cosmetics and medical markets. Leading companies such as PharmaResearch, APR, and LG Chem are actively utilizing these substances in their cosmetic products. Proteoglycan, extracted from salmon, is effective not only in enhancing skin elasticity but also in preventing and aiding the recovery of cartilage damage, making it useful in treating degenerative arthritis. Thanks to these benefits, demand continues to rise in the regenerative medicine and premium high-functionality skincare markets.
Neofect plans to expand its business into various product categories, including pharmaceuticals, medical devices, and cosmetics, based on these technologies. In particular, the company aims to secure new growth engines by expanding its existing rehabilitation medical device-focused portfolio into the "medical beauty tech" sector.
The market is also experiencing rapid growth. According to global market research firm Precedence Research, the global anti-aging market is expected to nearly double from $73 billion (101.92 trillion KRW) last year to $140.94 billion (196.78 trillion KRW) by 2034.
A Neofect representative stated, "After acquiring the exclusive licenses, we are preparing to expand our infrastructure and production facilities," adding, "To enhance quality competitiveness and achieve economies of scale in the dermacosmetic sector, we are considering mergers and acquisitions (M&A) with multiple companies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
